Hirsutism future or investigational therapies

Hirsutism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hirsutism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Echocardiography or Ultrasonography
Treatment
Medical Therapy Pharmacological therapy Non-pharmacological therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hirsutism future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hirsutism future or investigational therapies
CDC on Hirsutism future or investigational therapies
Hirsutism future or investigational therapies in the news
Blogs on Hirsutism future or investigational therapies
Directions to Hospitals Treating Hirsutism future or investigational therapies
Risk calculators and risk factors for Hirsutism future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]: Associate Editor(s)-in-Chief: ; Rasam Hajiannasab M.D.[2]

Overview

Fluridil is one of the new topical treatment options for hirsutism which is not available yet.

Future or Investigational Therapies

Fluridil (2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl) phenyl]-3-(2,2,2-trifluoroacetylamino)ropanamide) is a new topical antiandrogen agent and has been developed for hyperandrogenic skin syndromes.

A clinical study has shown that a 2% fluridil gel is a safe and effective treatment method of hirsutism and also has no effect on libido or sexual function but Fluridil is not available yet.